Melatonin is produced during the night and regulates sleep and circadian rhythms. Loss-of-function variants in MTNR1B, which encodes the melatonin receptor MT 2 , a G protein-coupled receptor (GPCR), are associated with an increased risk of type 2 diabetes (T2D). To identify specific T2D-associated signaling pathway(s), we profiled the signaling output of 40 MT 2 variants by monitoring spontaneous (ligand-independent) and melatonin-induced activation of multiple signaling effectors. Genetic association analysis showed that defects in the melatonininduced activation of G i1 and G z proteins and in spontaneous -arrestin2 recruitment to MT 2 were the most statistically significantly associated with an increased T2D risk. Computational variant impact prediction by in silico evolutionary lineage analysis strongly correlated with the measured phenotypic effect of each variant, providing a predictive tool for future studies on GPCR variants. Together, this large-scale functional study provides an operational framework for the postgenomic analysis of the multiple GPCR variants present in the human population. The association of T2D risk with signaling pathway-specific defects opens avenues for pathway-specific personalized therapeutic intervention and reveals the potential relevance of MT 2 function during the day, when melatonin is undetectable, but spontaneous activity of the receptor occurs.
INTRODUCTION
Type 2 diabetes mellitus (T2D) is characterized by high blood glu cose concentrations in the context of insulin resistance and impaired insulin secretion from pancreatic  cells (1) . The prevalence of T2D has increased over the last 20 years and closely parallels the moun t ing epidemic of obesity. G protein-coupled receptors (GPCRs) are promising drug targets for metabolic diseases, including T2D (2, 3) . Agonists of GPCRs, such as the glucagonlike peptide 1 receptor (GLP1R), are clinically used to improve glucose tolerance in T2D patients (4) . Furthermore, drugs targeting other GPCRs, such as the gastric inhibitory polypeptide receptor (GIPR), the free fatty acid receptor 1 (FFAR1; also known as GPR40), and the glucosedependent insulinotropic receptor (GPR119), are currently in clinical trials and at different stages of development for diabetes therapy (3) .
In addition to several environmental risk factors, T2D has a strong genetic basis. Genomewide association studies and their metaanalyses have identified more than 100 loci containing singlenucleotide poly morphisms (SNPs) that are statistically significantly associated with T2D risk and altered glycemic values or insulin secretion (5) . The common SNP rs10830963 is located in the unique intron of MTNR1B, which encodes MT 2 , the melatonin (MLT) receptor, and is statistical ly significantly associated with increased fasting plasma glucose con centrations, reduced early insulin response to glucose, and increased risk of both T2D and gestational diabetes mellitus (6) (7) (8) . The homo zygous T2Dassociated SNP [corresponding to a GG genotype; the wildtype (WT) sequence is CC] is associated with a twofold increase in cis MTNR1B messenger RNA (mRNA) abundance in human pan creatic islets compared with the amount in the islets of CC genotype carriers (7, (9) (10) (11) , suggesting that increased MLT signaling might be associated with an increased T2D risk. However, when we performed a largescale exon resequencing of MTNR1B, we found that only rare, nonsynonymous variants with a lossoffunction phenotype strongly associated with increased T2D risk (odds ratio of 5 when analyzed in aggregation) (12) . Considering these apparently contra dictory findings, the role of MT 2 signaling on T2D risk in humans remains unanswered.
MT 2 belongs to the MLT receptor family of GPCRs, which is com posed of MT 1 , MT 2 , and the orphan GPR50 based on their sequence homologies. However, only MT 1 and MT 2 and not GPR50 bind to MLT and do so with high affinity (13) (14) (15) . MLT is mainly secreted from the pineal gland in a circadian manner with high plasma concen trations during the night (16) . MLT receptors are involved in the reg ulation of sleep, circadian and seasonal rhythms, immune functions, retinal physiology, and glucose homeostasis (17) . How MLT modu lates glucose homeostasis in humans is not well understood. In rodent  cell lines, MLT decreases insulin secretion (18, 19) , whereas studies of isolated human islets showed that MLT stimulates insulin secretion (20, 21) . It is well known that MLT exerts opposing effects on specific functions in a speciesdependent manner (22) . Epidemiological studies demonstrated that people working on different shifts, compared to day workers, present with a marked dysfunction in nocturnal MLT secretion and a higher risk of cardiovascular disorders, metabolic dis eases (including T2D), and cancer. A 12year prospective study showed that decreased nocturnal MLT secretion in nurses working on rotat ing night shifts is associated with a higher risk of developing T2D (23) .
Several sites of MLT action are possible because MT 1 and MT 2 are present in many central and peripheral tissues, including insulin target tissues, such as liver, muscle, and adipose tissue (19, 24) . The amounts of mRNA transcripts for MTNR1A (encoding MT 1 ) and MTNR1B are very low or undetectable in human islets and only de tectable in a small subset of  cells (25) (26) (27) , raising questions about the relevance of human islets as an MLT target tissue (28) . In the hypothalamic suprachiasmatic nuclei, MT 1 and MT 2 regulate the circadian rhythms of the master clock in mammals, and disruption of central and peripheral circadian rhythms leads to metabolic dis orders, including T2D (29) (30) (31) . The T2Dassociated SNP rs10830963, which is in an intron unique to MTNR1B, affects the dynamics of MLT secretion (32) . Therefore, it is possible that the global dys regulation of MT 2 signaling contributes to T2D pathophysiology through the alteration of circadian rhythms.
Given that GPCRs can engage multiple distinct signaling path ways and that biased ligands alter the balance of activated signaling pathways (33, 34) , the objective of the current study was to assess the effect of all MTNR1B variants identified by Bonnefond et al. (12) on multiple pathways engaged upon MT 2 activation. We gen erated a "signaling signature" for each variant receptor to investi gate whether the association between MT 2 loss of function and T2D was linked to specific signaling defects. MT 2 has been described to activate three signaling pathways. Through G i/o proteins, MT 2 in hibits the production of cyclic adenosine monophosphate (cAMP) and stimulates extracellular signal-regulated kinase 1 and 2 (ERK1/2). In addition to engaging G i/o proteins, MT 2 also promotes the re cruitment of arrestin (35) . Here, we assessed the effects of spon taneous (ligandindependent) and MLTinduced activity of each MT 2 variant for these three pathways.
The "evolutionary action" (EA) deduced from in silico trace evo lution analysis (36) predicts the functional effect of a mutation based on the sensitivity of the site that is mutated and on the magnitude of the mutational substitution. We applied this evolutionary action analysis to correlate the experimental data with mutations in the MT 2 sequence. We then reassessed the genetic association data to investigate the effects of specific signaling defects on T2D risk. With this systematic multiparameter approach, we determined specific signaling defects related to MT 2 variation that are associated with T2D risk. This approach not only holds promise for identifying strategies to develop specific treatments or preventative measures for T2D but also is a method that will facilitate the targeting of spe cific diseaserelated pathway defects when implemented into drug discovery workflows. 2 To identify the pathways engaged by MT 2 , we used a combination of bioluminescence resonance energy transfer (BRET)-based and protein complementation-based sensors to assess G protein activa tion and arrestin recruitment by WT MT 2 . We compared the liganddependent activation of 10 individual G proteins by specific receptors known to couple to each G protein with the activation induced by MLTactivated MT 2 using a BRET assay that detects separation of the G subunits from G subunits (fig. S1A), and eval uated the activation of 15 individual G proteins by MLTactivated MT 2 using a BRET assay that detects the association of a G subunit with GPCRregulated kinase 2 (GRK2) ( fig. S1B ). Of the G protein subtypes assessed, only members of the G i/o family showed statis tically significant activation, with G i1 and G z having the most ro bust activation amplitude ( fig. S1, A and B) . Thus, we performed a concentrationresponse analysis for the MLTinduced activation of G i1 and G z . We also assessed the ability of MT 2 to spontaneous ly activate these two G proteins by comparing the differences in BRET signals in the absence of MLT in cells expressing or not ex pressing MT 2 ( fig. S1, C and D) . MT 2 showed spontaneous activity toward both G i1 and G z , and MLT promoted a concentration dependent increase in their activity with similar EC 50 (half maximal effective concentration) values for both G proteins. The opposite directions of the presented concentration response curves reflect the different natures of the biosensors used to test their activity, which results in a decrease in BRET for the sensor monitoring the separation of the G subunit from the G subunit (used for G i1 ) and the sensor detecting the interaction of the dissociated G with GRK2 (used for G z ). MT 2 also displayed spontaneous activity to ward the recruitment of arrestin2 in the absence of MLT, an activ ity that was concentrationdependently increased by the addition of MLT ( fig. S1E ).
RESULTS

Identifying pathways engaged by MT
To confirm signaling downstream of G proteins and arrestin2, we performed cAMP assays and ERK1/2 activation assays, respec tively. Both G i1 and G z inhibit the activity of adenylyl cyclases to inhibit cAMP production; therefore, we assessed the inhibition of forskolinstimulated cAMP production by MLTactivated MT 2 . MLT triggered a dosedependent reduction in cAMP concentration with maximal inhibition of about 30%, consistent with the coupling of MT 2 to G proteins that inhibit adenylyl cyclase activity ( fig. S1F ). Arrestins promote receptor internalization and desensitization of G protein-dependent signaling at receptors located at the plasma membrane (37) . In addition, arrestins function as independent signaling transmitters (38) or mediate sustained endosomal signal ing (39) (40) (41) (42) . Both G protein-mediated and arrestin-mediated signaling can activate ERK1/2. To determine whether MT 2 can stimulate ERK activation, we performed an ERK activation assay (43) and found that MLT stimulated a dosedependent increase in ERK activation in MT 2 expressing cells ( fig. S1G ).
Evaluation of spontaneous G i1 and G z signaling and -arrestin2 recruitment by MT 2 variants Subsequently, we monitored the effects of the 40 nonsynonymous MT 2 variants (including 38 rare and the 2 common p.G24E and p.K243R variants), which are distributed throughout the receptor (see fig.  S2 for variant positions in the receptor), on the direct activation of G i1 and G z proteins, downstream inhibition of forskolinstimulated cAMP production, and the recruitment of arrestin2, and ERK1/2 activation. To control for the potential influence of different cell sur face abundances on signaling activity, we assessed cell surface receptor abundance by enzymelinked immunosorbent assay (ELISA) for all tested forms of the variants and WT receptors ( fig. S3 ). Four mu tants are classified as lossofMLT binding (p.A42P, p.L60R, p.P95L, and p.Y308S) on the basis of results obtained in a radioligand bind ing assay (12) . We measured the spontaneous (agonistindependent) activation of G i1 and G z by the MT 2 variants. For WT MT 2 , the spon taneous activity represented 51.3 and 22.5% of the maximal MLT stimulated activity for G i1 and G z , respectively (fig. S1, C and D). Seventeen MT 2 variants displayed reduced spontaneous activation of G i1 , and 14 displayed reduced spontaneous activation of G z (Fig. 1, A We also determined the spontaneous recruitment of arrestin2 to the MT 2 variants. Similar to G protein activation, we observed high spontaneous arrestin2 recruitment for WT MT 2 , representing 70% of the maximal response ( fig. S1E ). Spontaneous arrestin2 re cruitment was statistically significantly reduced for 15 variants (Fig. 1C  and table S3 ). The four mutants that exhibit lossofMLT binding (p.A42P, p.L60R, p.P95L, and p.Y308S) did not display any sponta neous arrestin2 recruitment, confirming that the spontaneous arrestin2 recruitment monitored for the WT MT 2 was receptor dependent and does not represent an intrinsic feature of the assay. None of the variants showed increased spontaneous arrestin2 re cruitment (Fig. 1C) , suggesting that the constraints that restrict consti tutive activation of G proteins are different from those controlling spontaneous arrestin recruitment.
Evaluation of agonist-induced G i1 and G z signaling by MT 2 variants
The effect of MLT on G i1 or G z activation was also differentially altered by the variants. For each variant, full concentrationresponse curves were performed, and both the EC 50 (potency) and the maximal agonistmediated response (efficacy; E max ) were determined (Fig. 2,  fig. S4 , and tables S1 and S2). From this analysis, we grouped the variants into eight categories ( Fig. 2 and fig. S4 ): those that were pre viously classified as lossofMLT binding variants ( Fig. 2A and fig. S4A ), those that exhibited impaired signaling through all pathways (Fig. 2B  and fig. S4B ), those that exhibited impaired signaling in two or more pathways ( Fig. 2C and fig. S4C ), those with specific defects in MLT stimulated G protein-specific signaling (Fig. 2D and fig. S4D ), those with a specific defect in arrestin recruitment (Fig. 2E and fig. S4E ), those with a specific defect in ERK activation (Fig. 2F) , those that exhibited a gain of function (Fig. 2G) , and those that were similar to WT MT 2 ( fig. S4F ).
Similar to their reduction in spontaneous activity, most of the variants (p.A42P, p.L60R, p.A74T, p.P95L, p.S123R, p.V124I, p.R138C/ H/L, p.Y141F, p.T201M, p.R222H, p.I223T, p.F250V, p.Y308S, p.R316H, p.R330W, and p.A342V) were also deficient in coupling to both G pro teins, whereas five variants (p.G109A, p.M120I, p.M120V, p.R154H, and p.D246N) showed subtypespecific defects in MLTinduced G i1 and G z activation ( fig. 2 and fig. S4 ). Two variants (p.A359E and p.P36S) showed increased agonistpromoted G i1 activation (table S1), indicating that both loss and gainofMLT responsiveness can be found among natural variants. We examined the influence of the variants on signaling downstream of G i by monitoring inhibition of forskolininduced cAMP accumulation. The MLTinduced responses show that, in addition to the four lossofMLT binding mutants (p.A42P, p.L60R, p.P95L, and p.Y308S), markedly impaired cAMP responses were also observed for p.S123R, p.R138C/H/L, p.F250V, and p.R316H (Fig. 2, fig. S4 , and table S4). These data indicate that an impaired ability to reduce cAMP production is consistent with the defective ability of these variants to activate G i1 and G z . In some cases (p.A74T, p.M120I, p.V124I, p.Y141F, p.R154H, p.T201M, and p.D246N), defects in G i activity were observed with no effect on the measured cAMP. This is most likely due to the fact that whereas the assays detecting G protein activation are stochiometric, and are means ± SEM of at least three experiments. One-sample t test was performed to assess statistically significant differences between the WT receptor and the MT 2 variants. *P < 0.05, **P < 0.01, and ***P < 0.0001. See also tables S1 to S5 for complete data sets for the spontaneous activity of MT 2 variants. the production of cAMP is an amplified signal, making it more dif ficult to detect the effects of the mutations leading to the less severe impairment in G i activity.
Evaluation of -arrestin2 recruitment by MT 2 variants
Twentyfour variants were defective for their ability to recruit arrestin2 in response to MLT (table S3) . In addition to the four lossofMLT bind ing mutants, 15 MT 2 mutants that displayed impaired G i signaling (p.A74T, p.G109A, p.M120V, p.S123R, p.V124I, p.R138C/H/L, p.T201M, p.R222H, p.I223T, p.D246N, p.F250V, p.R316H, and p.A342V) and an additional five mutants with normal G i and cAMP signaling (p.L166I, p.R231H, p.E237K, p.S238G, and p.K243R) showed reduced arrestin2 recruitment (Fig. 2, fig. S4 , and table S3).
Evaluation of ERK signaling by MT 2 variants
ERK phosphorylation upon MLT stimulation was used as a proxy for activation. For WT MT 2 , ERK activation was fully blocked by the G i/o inhibitor pertussis toxin and was unaffected by RNAi (RNA interference)-mediated silencing of arrestin1 and arrestin2 ( fig. S5 ), indicating that ERK activation occurred downstream of G protein acti vation. All MT 2 variants that were impaired for both the G i /cAMP and arrestin2 pathways also exhibited reduced phosphorylation of ERK in response to MLT (Fig. 2, fig. S4 , and table S5). Other variants showed partially impaired ERK activation (p.A74T, p.V124I, and p.T201M) together with partial impairment of both G protein-mediated signal ing and arrestin2 recruitment or with a specific G i1 signaling defect (p.R154H) or with a specific G z signaling defect (p.M120I). Fur thermore, the ERK signaling-defective variant p.M146V was the only variant with normal G i /cAMP signaling and arrestin2 recruitment, suggesting the potential involvement of additional pathway(s) in medi ating MT 2 dependent ERK activation. The p.A359E variant differed from all of the others: It exhibited a substantially increased ERK re sponse (246% E max of the WT) (table S5), a property that extended to a lesser extent to G i1 activation and arrestin2 recruitment (Fig. 2) .
Evaluation of the relationship among signaling alterations exhibited by the MT 2 variants
To determine whether there was a link between the effect of the mu tation on spontaneous or agoniststimulated receptor activities, cor relations between the effects on the two parameters were performed for the different pathways ( Fig. 3A and fig. S6 , A and B). In addition, to assess the possible functional links between two pathways, correla tion between the effect on each pathway was performed in a pairwise manner (Fig. 3 , B and C). We also performed pairwise comparisons of spontaneous activity (fig. S6, C to E). Spontaneous G i1 and G z activation only modestly correlated with the corresponding MLT induced activation of G i1 (Fig. 3A , left) and G z (Fig. 3A, middle) . A typical example is the p.M120V variant, which exhibited markedly reduced spontaneous G i1 activity and had WTlike agoniststimulated activity (Fig. 3A, left) . Similar to the low correlation between sponta neous and agoniststimulated G protein activation, the correlation between spontaneous and MLTinduced arrestin2 recruitment was also low (Fig. 3A, right) . This lack of correlation between spontaneous and agonistinduced activity indicated that the modes of spontaneous and MLTinduced receptor activity were distinct with potentially dif ferent allosteric constraints. In contrast, there was a strong correlation between the spontaneous activation of G i1 and G z ( fig. S5C ) and between the MLTinduced activation of G i1 and G z (Fig. 3C , G i1 versus G z ). These correlations suggest that similar receptormediated activation modes control these two G i family members.
To test for a link between G protein-and arrestin2-dependent events, we correlated MLTinduced G i1 and G z activation and cAMP inhibition with MLTinduced arrestin2 recruitment (Fig. 3B) . We also tested the correlation between MLTinduced G protein activation and spontaneous arrestin2 recruitment ( fig. S5, A and B) and between spontaneous G protein activation and spontaneous arrestin2 recruitment (fig. S5, C to E). All showed moderate, yet statistically significant correlations, which contrasted with the tightly correlated G protein-dependent events (Fig. 3C) , indicating that G protein activation and arrestin recruitment rely on at least partially independent processes. Together, these data reveal a general trend of reduced spontaneous and MLTinduced activity for MT 2 mutants at the level of arrestin2 recruitment and G protein activation and highlight the independent nature of these two processes.
Generation of signaling signatures of MT 2 variants
To represent the signaling characteristics of the different variants, the overall signaling efficiencies of the WT and mutant receptors were assessed for each outcome using the operational model of Black and Leff (44) as modified by Kenakin et al. (45) . The transduction coeffi cient log(/K A ) was used as an indication of the signaling efficiency of each variant, and the comparison between WT receptor and each of the variants was then obtained by subtracting the transduction coef ficient log(/K A ) of the mutants from that of the WT and expressed as log(/K A ) (tables S1 to S5). We plotted radial graphs of the calcu lated log(/K A ) together with the spontaneous and MLTinduced signaling efficacy to represent a signaling signature for each MT 2 variant. This representation revealed several groups of variants with distinctive signaling signatures (Fig. 4) 
Evolutionary action analysis of MT 2 variants
The large amount of functional data collected here provides a tool to validate in silico models predicting variant receptor functionality.
One of these models, evolutionary action (EA) (36) predicts the effect of a variant on protein function using the relative importance of each residue based on evolutionary divergence, evolutionary trace (46), combined with the likelihood to observe a given amino acid substitu tion for another across evolution measured as the substitution log odds (36) . On the basis of these phylogenetic patterns of variation, an EA score from 0 (benign) to 100 (highly detrimental or impactful) was assigned for each MT 2 variant (Fig. 5A ). To assess whether these empirical EA scores could be predictive of the functional impact ob served in the signaling assays, we assigned a "phenotype score" to each variant that was calculated by averaging the 13 values corresponding to the normalized functional parameters used for the signaling signa tures. The predictive EA scores correlated with the experimentally determined phenotype scores (Fig. 5B) , indicating that the degree of measured functional divergence of the variants from the WT cor related with the degree of predicted evolutionary divergence. Overall, the good correlation of phenotypic scores with EA scores confirmed the robustness of evolutionary action in predicting the effect of vari ants on receptor fitness.
Association between functional MT 2 defects and T2D risk On the basis of the different signaling signatures observed for the MT 2 variants, they clustered into nine groups. For each of these nine groups, the association between T2D risk and the aggregation of the variants was assessed by the kernelbased adaptive cluster method (47) as previously described (Table 1 ) (12) . By applying Bonferroni correction, we considered P < 0.0056 to be statistically significant, and we considered P values between 0.05 and 0.0056 to be a trend of association. We found that rare variants with defects in MLTinduced activation of G i1 or G z or in spontaneous arrestin2 recruitment were the most strongly and statistically significantly associated with increased T2D risk. For example, rare variants with defects in MLT induced activation of G i1 had an odds ratio of 3.25 with a 95% con fidence interval of 1.73 to 6.10 and a P value of 2.4 × 10 −4 (Table 1) . In contrast, all of the other groups characterized by different signaling defects showed only a trend of association with T2D. The absence of an association of defective MLTinduced arrestin2 recruitment with T2D is consistent with the observation that the frequent p.K243R variant (rs61747139), which exhibits defective MLTinduced arrestin2 recruit ment, is not associated with T2D (12, 48) . Furthermore, the "neutral" rare variants were not found to be associated with T2D risk (Table 1) . This is consistent with lack of risk association between T2D and the common p.G24E variant (rs8192552) (12, 48) , which is also neutral.
DISCUSSION
Our extensive functional genomics study on 40 rare or very rare MT 2 variants identified an overall lossoffunction phenotype for many parameters and pathways measured. The observed disconnection of spontaneous versus MLTinduced activity as well as G protein-versus arrestin-dependent signaling of these variants enabled us to dissect the respective contributions of each of these parameters and to reveal the strongest associations to increased T2D risk with defective MLT induced G i1 and G z activation and defective spontaneous arrestin2 recruitment.
Connecting rare GPCR variants with common diseases: A general framework
The present study provides a framework to correlate alterations in specific signaling parameters with the risk to develop a common disease. Our study is distinct because the functional basis or relevance of most genetic risk factors remains either unknown or is restricted to a simple loss and gainoffunction phenotype classification. It is now well established that the intracellular signaling of GPCRs is highly in terconnected, involving multiple signaling pathways. Defining the full functional profile or signaling signature of a GPCR and its variants is im portant to understand the functional defect linked to diseaseassociated receptor variants. Whereas the number of such GPCR variants has been largely underestimated because of their low frequency, system atic wholegenome sequencing projects revealed a large interindividual diversity when considering large populations, a relevant scenario in the case of common diseases like T2D.
For genes coding for nonodorant GPCRs in humans, an average of 32 nonsynonymous variants have been estimated to exist for each GPCR in a sample of 10,000 individuals (49, 50) . This estimation provides a first measure of the number of rare GPCR variants in the human population and gives an idea of the future challenges in terms of their functional characterization to understand their effect on dis eases. In terms of the number of variants, the 40 variants identified in the MTNR1B gene in a cohort of ~10,000 individuals (12) seem to fit with this assumption. As demonstrated by our study, such a num ber of variants can be sufficient to identify receptor defects at the level of individual signaling pathways. Application of the operation al model of Kenakin and Christopoulos (34, 45) , originally designed to compare the relative signaling efficiency of different ligands, was very instructive in defining an integrative measure for signaling de fects that went beyond the determination of the isolated signaling parameters. This is exemplified by the p.R154H variant for which defects in G i1 activation only became visible at the level of the Values of variants with enhanced properties ranged from 0 to +1, and those with impaired properties ranged from 0 to −1. The scale of all radial graphs ranged from −1 to +1. S, spontaneous; Em, agonist-mediated efficacy; , log(/K A ). See also tables S1 to S5 for complete data sets for spontaneous and agonist-mediated signaling activity of the MT 2 variants. log(/K A ) transduction ratio because it integrates both potencies and maximal efficacies. A decrease in the maximal agonistmediated efficacy and a rightward logEC 50 shift were observed for this variant but were not statistically significant. However, when both maximal efficacy and potency were integrated, the global response depicted by log(/K A ) value was statistically significantly reduced compared to that of the WT receptor. A good correlation was seen between the EA score of MT 2 variants and the corresponding experimentally de termined phenotypic scores, which indicates the usefulness of the EA score to predict the functional effect of a specific GPCR variant. The EA score might therefore be applied to obtain a first classification of GPCR variants before entering into largescale functional studies. To gether, our data provide an operational template for the evaluation of the functional effect of GPCR variants on common traits and diseases.
Specific pathway parameters of MT 2 variants associated with T2D risk
Given that GPCRs, such as MT 2 , can signal through various cascades and that different variants have the potential to modulate one or more signaling parameters, a complete functional characterization is re quired to understand the full effect of receptor variants on disease risk. Here, we determined both spontaneous and MLTinduced MT 2 activity for five signaling events (G i1 and G z activation, inhibition of cAMP production, arrestin2 recruitment, and ERK1/2 activation). Ten of 38 rare receptor variants had a phenotype that was indistin guishable from that of the WT receptor and were therefore classified as neutral variants. The 28 other variants showed functional defects compared to the WT receptor. Only the variant p.A359E showed a robust gainoffunction phenotype with 246, 145, and 130% increases in the E max values of ERK activation, G i1 activation, and arrestin2 recruitment, respectively. It would be interesting in a followup study to determine the effect of this increased MT 2 function on an individ ual's metabolism. Together, our data show that lossoffunction MT 2 variants at different functional levels are associated with increased T2D risk. Detailed genetic association analysis detected three param eters that stand out in terms of the statistical significance of associa tion with T2D risk: MLTinduced activation of G i1 (19 variants) and G z (22 variants) and spontaneous arrestin2 recruitment (15 vari ants). The independence of signaling events associated with G protein activation and arrestin2 recruitment was further highlighted by the poor correlation between them for the 40 MT 2 variants. The impor tance of G i1 activation underlines the general importance of this wellcharacterized pathway for MT 2 . The activation of G z by MT 2 has not been reported previously, but the importance of impaired G z coupling for the association with T2D risk is of interest because the tissue distribution and GPCR coupling profile of G z are more re stricted than those of G i1 . G z is mainly expressed in different brain regions and in retinal ganglion cells (51, 52) , all regions for which MLT receptor expression has been reported (53, 54) . In addition, the in trinsic GTPase (guanosine triphosphatase) activity of G z is very slow, with a hydrolysis rate that is 200fold slower than that determined for any other G proteins (55) . These results introduce G z as a previously un characterized player in MT 2 signaling with a potential effect on T2D risk.
Although the recruitment of arrestin2 to MT 2 in transfected cells has been reported (56, 57) , the physiological importance of this phenomenon and its robustness in a cellular context expressing en dogenous MT 2 receptors remain unclear. MT 2 has indeed a poor capacity for MLTinduced arrestin recruitment, an observation that was confirmed here. Part of this difficulty to reveal ligandinduced arrestin2 recruitment might be explained by the high degree of spontaneous arrestin2 recruitment observed here. This spontaneous activity was completely lost for several variants, including the four lossofMLT binding mutants, which suggests that the measured spon taneous activity is receptordependent. Arrestins are important reg ulators of GPCR function and scaffolding platforms for many signaling complexes (38) , but the role of arrestin recruitment in MT 2 func tion in peripheral and central tissues is currently unknown. Our re sults indicating an association between the spontaneous recruitment of arrestin2 to the receptor and T2D risk point to a possible import ant role of arrestin2 recruitment to MT 2 .
Another unexpected and potentially relevant outcome of our study is the association of spontaneous MT 2 activity, namely, arrestin2 re cruitment, with T2D risk. The notion that spontaneous and ligand induced receptor activation of the 40 variants should be considered as independent signaling properties is supported by the poor correlation of these two parameters for three signaling pathways (G i1 activation, G z activation, and arrestin2 recruitment), which enabled us to de termine the effects of both parameters independently on disease risk. Spontaneous MLT receptor activity was previously described for obtained for the overall correlation. Correlation value was statistically significant, P < 0.0001. The A42P MT 2 variant was excluded from the R 2 calculation because of the known detrimental effect of proline residues on general protein structure. See also tables S1 to S5 for complete data sets for spontaneous and agonist-mediated signaling activity of the MT 2 variants. G proteins in transfected cells and tissues (58) (59) (60) . Our study shows that MT 2 also spontaneously recruits arrestin. The importance of consti tutive GPCR activity in disease has been discussed in the mesolimbic dopamine system for cannabinoid 1, 5HT 2C , and opioid receptors (61) . Spontaneous activity as a risk factor for T2D is particularly inter esting in the case of MT 2 , given that its cognate ligand, MLT, is only produced during the night and absent during the daytime because of a direct inhibitory effect of light on MLT synthesis (62) . This opens the interesting possibility that MT 2 function might be physiologically relevant not only during the night but also during the day, at a time when the regulation of plasma insulin concentrations is most impor tant in humans.
Whereas the link between the MTNR1B gene and T2D risk has been firmly established in humans (8) , the molecular mechanism and relevant MLT target tissues in humans remain largely unknown. Studies on rodent pancreatic  cells indicate that these cells are relevant MLT targets in which MT 1 or MT 2 activation inhibits insulin secretion through the G i /cAMP pathway (63) . However, studies conducted with human pancreatic  cells did not have clear conclusions, and several studies using singlecell transcriptome profiling and RNA sequencing detected MTNR1B transcripts only in a minor fraction (5%) of human islet cells and at extremely low concentrations (27, 64) , questioning the physiological relevance and effect of MTNR1B expression in the hu man pancreas. Functional studies on the common SNP rs10830963, located in the intron of MTNR1B, showed a twofold increase in MTNR1B mRNA abundance in human pancreatic islets of GG T2D risk allele carriers (9) . However, the functional importance of this observation remains unclear because increased amounts of mRNA transcripts do not necessarily result in increased numbers of receptors. Furthermore, even if an increase in receptor number occurs, this does not necessar ily result in an increased signaling capacity because of the presence of spare receptors or chronic receptor desensitization.
Together with the currently available data, the initially proposed inhibitory action of MT 2 in human  cells warrants revision and may be too simplistic. Other potential physiological outputs and MLT target tissues should be considered. Among those are the welldocumented effect of MLT on the circadian rhythm of the hypothalamic master clock and the effects on insulin target tissues, such as the adipose tissue (17) . Without having clarified this im portant point, validation of our results obtained in the human embryonic kidney-293(HEK 293) model system into a physiologi cally relevant context remains challenging. Our results provide hints about the most relevant signaling pathways potentially involved, which are the activation of G i1 and G z and the recruitment of arrestin2. These results will direct future research for the relevant physiological outputs of MLT action. The finding that spontaneous receptor activity also contributes to T2D will be important in guid ing future studies in humans by also considering the effects of MT 2 during the daytime, when MLT is not produced.
In terms of therapeutic perspectives, both medical intervention and lifestyle recommendations can be envisioned. The predominant defects observed in MT 2 variants are decreased E max values, suggesting that improving the residual responsiveness in these patients is a pos sible therapeutic strategy. Because most of the lossoffunction mutants were defective for G protein activation and arrestin2 recruitment, an optimal treatment should aim to improve both components. In terms of lifestyle recommendations, future studies will have to establish whether carriers of MT 2 variants suffer from MLTspecific dysfunctions, such as sleep problems or circadian misalignment of sleepwake cycles with feeding rhythms. If this is the case, carriers of MT 2 variants could benefit from specific lifestyle recommendations to decrease their T2D risk. Because carriers of MT 2 variants are rare or very rare, such interventions should be seen in the context of personalized medi cine. On the basis of the signaling signatures established in our study, patient groups might be identified that would benefit from a similar treatment. Similar examples of other GPCRs are melano cortin MC4 receptor mutants, which are associated with severe early onset obesity for which defective cell surface expression can be rescued with pharmacological chaperones (65) , and gainoffunction mutants of the chemokine receptor CXCR4 identified in patients with the Warts, Hypogammaglobulinemia, Immunodeficiency, and Myelokathexis syndrome (WHIM) syndrome for which the CXCR4 antagonist AMD3100 is currently in clinical trials (66) .
Our study further highlights an oftenneglected issue, which is the time of blood sampling or functional examination of patients to obtain meaningful results when trying to understand the biology of the MLT system. Apart from the circadian secretion profile of MLT, the constitutive MT 2 activity and its potential importance during the day time, when MLT concentrations are low, should also be taken into account in this respect. Finally, the set of 40 natural MT 2 vari ants will constitute a rich source for future structurefunction studies of biased receptor signaling.
Conclusion
We provide here a comprehensive framework for the functional characterization of GPCR variants that can serve as a template for future studies on further GPCRs. Our results on rare MT 2 variants demonstrate the association of the lossoffunction phenotype with T2D risk, which served as a basis for the dissection of the specific signaling events most statistically significantly associated with the disease. The two main signaling modules of GPCRs, mediated by G proteins and arrestins, both seem to contribute to disease risk. Our finding of the association of T2D risk with spontaneous MT 2 activity should provide insights with respect to circadian timing, an important aspect of MLT research. The information on disease associated signaling pathways will be valuable for future studies in defining the still unknown functionally relevant outputs linking MT 2 to T2D risk. This information will guide future drugscreening pro grams intended to improve MT 2 function.
MATERIALS AND METHODS
Plasmids and reagents
The 6mycMT 2 /pcDNA5/FRT plasmids encoding WT MTNR1B and the 40 MTNR1B variants were previously described (12) . The 3mycMT2/ARMS2/ProLink (PL) plasmids encoding WT MTNR1B and its variants were generated by subcloning the coding regions of MTNR1B from the 6mycMT2/pcDNA5/FRT plasmids into the pCMVPL expression vector, pCMVARMS2PK2 (DiscoverX). The resulting plasmid encoded in the C terminus the PL, a small enzyme donor fragment of galactosidase (gal) complementary peptide, fused to the target receptor. All constructs were verified by Sanger sequencing (Institut Cochin Sequencing Facility). MLT was obtained from Tocris Biosciences.
Cell culture and transfection HEK 293T cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and penicillin/streptomycin. HEK 293 cells stably expressing a arrestin2-gal-enzyme acceptor fusion protein (DiscoverX) were maintained in the same culture conditions, but with the addition of hygromycin B to maintain ex pression of the transgene. All cells were transfected with PEI (polyethylenimine) (Polysciences Inc.) or XtremeGENE 9 (Roche Diagnostics) according to the manufacturer's instructions.
Analysis of cell surface receptor expression
ELISAs were performed as previously described (67) using the mouse antimyc antibody and a horseradish peroxidase-conjugated mouse immunoglobulin G (IgG) wholesheep secondary antibody (Sigma).
BRET assay G i1 activation was assessed by measuring BRET between RlucIIG i1 and GFP10G2 upon treatment of HEK 293 cells cotransfected to express G 1 , receptor, and BRET sensors with MLT (68). This BRET pair was also used for the screening of G proteins activated by MT 2 , ex cept for RlucIIG s , RlucIIG z , RlucIIG q , and RlucIIG 12/13 . For these RlucIItagged sensors, GFP10G 1 was used given that optimal responsive window is generally obtained using these BRET sensor pairs for these G proteins ( fig. S1A ). For this G protein screening, vasopressin receptor type 2 was used as a positive control for G s activation, whereas muscarinic type 2, angiotensin type 1, and TP receptors were used as positive controls for G i/o , G q , and G 12/13 , respectively. For G z activation, the MLTinduced increase in BRET between RlucIIG 5 and GRK2GFP10 was monitored in the pres ence of G z , G 1 , and the receptor. The same BRET pair was also used for the screening of G proteins activated by MT 2 ( fig. S1B ). Transfected cells were plated in polydlysine-pretreated 96well white microplates (100 l per well; Greiner). Fortyeight hours after trans fection, the cells were washed with Dulbecco's phosphatebuffered saline, and then Tyrode's buffer was added. After the addition of agonist, the cells were incubated for 10 min at 37°C, and coelentera zine 400a (2.5 M; NanoLight Technology) was added 5 min before BRET reading in a Synergy Neo Microplate reader (BioTek) (accep tor filter: 515 ± 30 nm; donor filter: 410 ± 80 nm). Net BRET rep resents the BRET signal subtracted by the BRET monitored in the absence of a GFP10tagged sensor. BRET refers to the difference in net BRET recorded from cells treated with agonist and cells treated with vehicle. For the agonist doseresponse curves, the percentage of the response of the WT receptor was calculated from the BRET value obtained from a given variant divided by the BRET obtained from the WT receptor in the same experiment. Spontaneous G i1 or G z activation was calculated from the variant BRET value divided by the BRET obtained from the WT receptor in the same experi ment, where BRET here represents the difference in basal net BRET (vehicle only) in cells expressing biosensors and the receptor and the basal net BRET monitored in cells expressing biosensors only (mock).
Homogeneous time-resolved fluorescence-based cAMP assay
The intracellular concentrations of cAMP were determined in cells transiently expressing MT 2 or one of the 40 MT 2 variants in the presence of 2 M forskolin and after 30 min of stimulation with MLT at room temperature by HTRF (homogeneous timeresolved fluorescence) using the "cAMP femto2" Kit (Cisbio) according to the manufacturer's instructions.
Analysis of -arrestin2 recruitment
The PathHunter assay (DiscoverX) was used to measure interactions between MT 2 and arrestin2 as previously described (43) . HEK 293 cells stably expressing a fusion protein of arrestin2 with a larger fragment of gal, called enzyme acceptor, were transiently trans fected with the 3mycMT2/PL plasmids. Two days after transfection, the medium was replaced with AssayComplete Cell Plating 4 Reagent (DiscoverX) containing MLT, and the cells were incubated for 2 hours at 37°C. Activation of the MT 2 /PL stimulates the binding of arrestin2-enzyme acceptor fusion protein to the PLtagged MT 2 and forces com plementation of the two gal enzyme fragments, resulting in the formation of an active gal enzyme. This interaction leads to an increase in enzyme activity that can be measured with chemilumi nescent PathHunter Detection reagents (DiscoverX; www.discoverx. com/arrestin) and represents arrestin2 recruitment to the receptor. Luminescence signal was determined after 60 min of incubation at room temperature. ; PerkinElmer) in HEK 293T cells transiently express ing the MTNR1B or the MTNR1B variants, as previously described (69) . Given that the peak of pERK phosphorylation was previously observed for MT 2 at 5 min after MLT stimulation (12) , this time point was chosen to test the ability of MT 2 variants to activate ERK in MLT doseresponse curves.
Measurement of pERK1/2 abundance
Evolutionary action analysis
The predicted effect of each variant within the MT 2 receptor was cal culated, as previously described, (36) using the amino acid sequence deduced from the MTNR1B gene for the query.
Statistical analysis
LogEC 50 , logIC 50 (half maximal inhibitory concentration), and agonist induced E max values were determined by nonlinear regres sion with a variable Hill slope using GraphPad Prism software (ver sion 6.0). For each assay, the agonistinduced E max value for every MT 2 variant was normalized as a percentage of the maximal MLTstimulated response of the WT receptor (set at 100) monitored in parallel with the receptor variant. The doseresponse curves were fitted to an operational model of agonism designed by Kenakin and Christopoulos (34, 45) to obtain log(/K A ) values for the WT receptor and its variants. Normally, an agonist is set as a reference agonist, against which withinpathway comparisons for the same receptor to other agonists can be made and expressed as log(/K A ). Here, with inpathway comparisons were made between MT 2 variants and the WT receptor. For each variant, the spontaneous activation of G i1 , and of G z , and spontaneous recruitment of arrestin2 activation were expressed as a percentage of that of the WT receptor. Normalized differ ence was calculated on values corresponding to the spontaneous activa tion, agonistinduced E max , and log(/K A ) to fit a −1 to +1 scale using the following formula: (variant -WT)/(variant + WT). In the case of log(/K A ), before normalization, the antilogs were first calculated and then were fitted to the aforementioned formula. Positive and negative values represent mutations with better or worst responses, respectively, than those of the WT receptor. Subsequently, logIC 50 , logEC 50 , agonistinduced E max , and log(/K A ) values were expressed as means ± SEM of the indicated number of experiments (n). Statis tical analysis for logIC 50 , logEC 50 , and agonistinduced E max was performed by comparing independent fits with a global fit that shared the selected parameter, whereas a onesample t test was used to examine the mean differences between WT MT 2 and its variants for the values corresponding to the spontaneous activation and log(/K A ) ratios.
T2D case-control association study As previously described (12) , rare MTNR1B variants (with a frequen cy <1%) were analyzed in aggregation according to their functional effect. In a T2D casecontrol study including 2186 individuals with T2D and 4804 controls with normal fasting glucose concentrations, we assessed the effect of these aggregated variants on T2D risk through the kernelbased adaptive cluster method (47) embedded in a logistic regression model adjusted for age, gender, and body mass index. Following the Bonferroni correction, a P < 0.0056 (= 0.05 ÷ 9; where 9 was the number of independent tests performed in the present study) was considered to be statistically significant, whereas a P value between 0.05 and 0.0056 was considered nominal. These statis tical analyses were performed through R 2 . All samples were collected with appropriate informed consent with their use in the present study. All cohort studies followed ethical principles defined in the Helsinki declaration, and they were approved by local ethical committees from Lille (France), Paris (France), Poitiers (France), and Cambridge (UK).
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